About 30,360 results

Interval FITs could cut colonoscopies in those at above-average risk
MDedge Family Medicine; Jim Kling

Jan 18th, 2023 - In a new retrospective analysis of patients with above-average risk of colorectal cancer, multiple negative fecal immunohistochemical tests (FITs) were associated with a lower risk of advanced neoplasia. The findings suggest that multiple negative FITs could potentially identify individuals in high-risk surveillance who aren’t truly high risk, which could in turn ease the logjam of colonoscopie.

Prevalence of colorectal neoplasia 10 or more years after a negative screening colonoscopy

Jan 17th, 2023 - About The Study: The results of this study suggest that advanced colorectal neoplasm prevalence at screening colonoscopies conducted 10 or more years after a negative screening colonoscopy is low. Extension of the currently recommended 10-year screening intervals may be warranted, especially for female and younger participants without gastrointestinal symptoms. Authors: Thomas Heisser, M.Sc., o...

Hyperpigmented Papules on the Tongue of a Child
Helena Drolshagen, MD, Blake Chandler, MD et. al.

Jan 3rd, 2023 - The Diagnosis: Pigmented Fungiform Papillae of the Tongue Our patient’s hyperpigmentation was confined to the fungiform papillae, leading to a diagnosis of pigmented fungiform papillae of the tongue (PFPT). A biopsy was not performed, and reassurance was provided regarding the benign nature of this finding, which did not require treatment.

Doctors Who Choose Private Practice; Patients With Cancer Sue for Psilocybin; and Mindfulness, Exercise Don't Improve Memory

Dec 14th, 2022 - Doctors Who Choose Private Practice Some doctors buck the trend of getting corporate jobs and have chosen to return to private practice for many reasons. Even so, the pendulum has recently swung toward employment: Fewer than half of all physicians now work in private practice, the American Medical Association reports. But some doctors have left jobs and opened their own businesses because they ...

New Oral SERD Elacestrant -- for Which Breast Cancer Patients?

Dec 14th, 2022 - SAN ANTONIO — Updated results with the investigational oral selective estrogen receptor degrader (SERD) elacestrant give a hint of where it could find a place in the treatment paradigm for estrogen receptor positive (ER+) and HER2- advanced or metastatic breast cancer. Elacestrant is currently awaiting approval from the US Food and Drug Administration, with a decision expected in February. Data...

T-DXd: 'Remarkable' Survival Gains in Advanced Breast Cancer

Dec 14th, 2022 - SAN ANTONIO —Trastuzumab deruxtecan (T-DXd, Enhertu) has yielded significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival for patients with advanced HER2+ breast cancer when used as second-line and in later lines of therapy, new data confirm. However, the reports also highlighted the potential problem of interstitial lung disease (ILD) as an adv...

Low Risk of ALCL With Postmastectomy Implant Reconstruction

Dec 14th, 2022 - While there has been growing awareness of the risk of developing anaplastic large-cell lymphoma (ALCL) following cosmetic breast implant surgery, to date, there has been no study specifically concerning the risk of this complication among women who undergo implant reconstruction after a mastectomy. A new study, which the authors believe provides the first population-based estimate of the risk o...

Change Makers: Princess Ghida on Fighting Cancer in the Arab World

Dec 14th, 2022 - Dr John Whyte speaks with Princess Ghida Talal about cancer treatment and research efforts in the Arab World and the importance of addressing taboos and providing cancer care to everyone who needs it. This transcript has been edited for clarity. John Whyte, MD: Welcome, everyone. I'm Dr John Whyte, the chief medical officer at WebMD, and you're watching Change Makers: The Future of Health. Canc...

ACG 2022: Colorectal Cancer Screening, and GI and Liver Disease

Dec 13th, 2022 - This transcript has been edited for clarity. Hi. I'm Dr Vivek Kaul, and I'm a professor of medicine in the Division of Gastroenterology and Hepatology at the University of Rochester Medical Center in Rochester, New York. It's my great pleasure to collaborate once again with WebMD and Medscape this year, and this edition focuses on the topics I thought would be appealing to our primary care coll...

Alloantibody Data Exchange Would Save Lives, Reduce Costs

Dec 13th, 2022 - NEW ORLEANS — Save lives, save money. What's not to love? That's the claim made for a proposed national exchange or registry of data on alloantibodies. These are antibodies that develop in response to foreign red blood cells in individuals who undergo repeated blood transfusions, such as patients with sickle cell disease, although they can also occur after pregnancy and transplants. A central r...

Cancer Patients Struggle to Access Psilocybin Before They Die

Dec 13th, 2022 - In March 2020, when the world was struck by the news of the COVID-19 pandemic, Erinn Baldeschwiler received her own gut punch. She was diagnosed with stage IV metastatic breast cancer and was given about 2 years to live. Then 48, the mother of two teenagers had just started a new chapter in her life. She'd gotten divorced, moved to a new home, and left a small business she had spent 18 years cu...

Oral SERD Camizestrant Prolongs PFS vs Fulvestrant in Breast Cancer

Dec 13th, 2022 - The investigational selective estrogen receptor degrader camizestrant was associated with significantly longer progression-free survival for women with advanced estrogen receptor–positive, HER2-negative (ER+/HER2–) breast cancers, compared with the first-generation SERD fulvestrant Faslodex, in the SERENA-2 trial, shows a study recently presented at the San Antonio Breast Cancer Symposium. Amon...

CTC-guided Therapy Beats Physician Choice in Metastatic Breast Cancer

Dec 13th, 2022 - SAN ANTONIO — When choosing between chemotherapy and endocrine therapy for patients with hormone receptor (HR)+/HER2- metastatic breast cancer, allowing the results from a blood test that measures circulating tumor cell (CTC) count to overrule physician's choice of therapy can significantly improve overall survival. But are these results enough to change clinical practice? One expert reacting t...

Chemotherapy Meets Its Match Against Aggressive ER+/HER2– Breast Cancers

Dec 13th, 2022 - SAN ANTONIO – Results of a study being hailed as practice changing showed that, for pre- or perimenopausal women with aggressive hormone receptor-positive, HER2-negative (HR+/HER2–) untreated breast cancers, the combination of the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor ribociclib (Kisqali) and endocrine therapy offers a safer and equally efficacious alternative to combination chemothera...

The Role of Cultural Humility in Addressing Disparities in Lung Cancer Treatment: How Can Physicians Make a Difference?

Dec 13th, 2022 - This transcript has been edited for clarity. Jacob Sands, MD: I'm Dr Jacob Sands, thoracic medical oncologist at the Dana-Farber Cancer Institute. Welcome to Medscape's InDiscussion series on lung cancer. Today, we'll be discussing disparities in lung cancer diagnosis and treatment. But first, let me introduce my guest, Dr Narjust Florez, associate director of the Cancer Care Equity Program, a ...

Key Research on TNBC: Top 5 Picks From SABCS

Dec 13th, 2022 - SAN ANTONIO — While major reports on hormone receptor (HR)–positive breast cancer took center stage at the San Antonio Breast Cancer Symposium (SABCS) 2022, research highlighting new findings in triple-negative breast cancer (TNBC) stood out as well. Medscape Medical News spoke with SABCS program director Virginia Kaklamani, MD, leader of the Breast Cancer Program at UT Health, San Antonio, and...

Adagrasib (Krazati) Approved for KRAS-Mutated NSCLC

Dec 13th, 2022 - The US Food and Drug Administration (FDA) has granted accelerated approval to adagrasib (Krazati) for use in adults with KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer (NSCLC) that has progressed on at least one prior systemic therapy. Suitability for this therapy is to be determined by an FDA-approved test. The agency also approved two companion diagnostics: Qiagen...

Melanoma Mortality Rates Fell in 2010s as New Therapies Took Hold

Dec 13th, 2022 - A new generation of treatments appears to have caused U.S. melanoma mortality rates to plunge between 2013 and 2017 for the first time in 4 decades, a new study finds, although the dip appeared to stabilize over the next 2 years. Dr Navkirat Kahlon "This data is very encouraging and represents the real-world effectiveness of these newer therapies, which include immunotherapies and targeted ther...

High Response Rates With T-DXd in Early HER2-Low Breast Cancer

Dec 13th, 2022 - SAN Antonio – How do you shoot at an invisible target? It seems counterintuitive, but trastuzumab deruxtecan (T-DXd) (Enhertu), which combines an antibody targeted to HER2 with a toxic payload, showed promising preliminary activity against localized hormone receptor–positive breast cancers with only low levels of HER2 expression (HR+/HER2-low). Dr Aditya Bardia n the investigator-initiated TRIO...

Steep Price for Surviving Childhood Lymphoma: Epigenetic Aging

Dec 13th, 2022 - NEW ORLEANS — Children with Hodgkin lymphoma can be cured with intensive chemotherapy, radiation, and other modalities, but a large majority of patients who survive into adulthood may pay a steep price years later in terms of accelerated aging and neurocognitive impairment. The findings come from a study of nearly 500 individuals in their late 30s, of whom 215 were adult survivors of pediatric ...